LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Presents Diagnostic Innovations to Enhance Patient Care at AACC 2022

By LabMedica International staff writers
Posted on 20 Jul 2022
Image: Abbott celebrated 50 years of diagnostic innovations at AACC 2022 (Photo courtesy of Abbott)
Image: Abbott celebrated 50 years of diagnostic innovations at AACC 2022 (Photo courtesy of Abbott)

Abbott Diagnostics (Lake Bluff, IL, USA) is offering one-on-one and group demonstrations of its latest diagnostic offerings at the 2022 AACC Clinical Lab Expo, including its next generation of Alinity systems that are designed to simplify diagnostics and help deliver results. In addition, Abbott will be providing demonstrations of its GLP systems Track, AlinIQ Digital Health solutions, hematology, molecular, diabetes care and point of care solutions.

Visitors at the Abbott AACC 2022 booth can learn new ways to achieve measurably better healthcare performance with its personalized core diagnostics solutions consisting of Resourceful Advocates, Harmonized Systems and Intelligent Insights. During its product demonstrations at the event, visitors can explore Abbott's next generation of Alinity systems that uses technology to help redefine and improve operational productivity and confidence in the laboratory. The Alinity family is harmonized across key laboratory disciplines, streamlining critical interactions between individuals, systems and information, and enabling users to redefine performance in the laboratory and across the institution.

The Alinity family comprises the Alinity ci-series integrated clinical chemistry & immunoassay system combining up to four modules in multiple configurations to meet the laboratory's needs and maximize operational efficiency. The Alinity c is a compact clinical chemistry system that maximizes testing throughput with high-quality assays to deliver efficient and accurate performance. The ALINITY I is a compact immunoassay system that utilizes proven CHEMIFLEX chemiluminescent detection technology to provide greater confidence in results. The Alinity m is a fully integrated, automated, high-throughput molecular diagnostics analyzer with high-quality assays that delivers the next level of flexibility and efficiency to molecular labs.

At AACC 2022, Abbott is also demonstrating GLP systems Track that allows users to easily modify their track for future changes and maximize floor space while transforming the laboratory from 2D to 3D. GLP systems Track minimizes track implementation time, maximizes uptime with infinite redundancy, optimizes workflow, and decreases turnaround time system to meet the laboratory’s needs. In addition, Abbott will demonstrate how AlinIQ Always On services can help labs achieve operational efficiency and increase productivity by avoiding unexpected downtime. AlinIQ Always On Services utilizes Active Sense Technologies, Resourceful Advocates and Disciplined Processes to offer instrument health monitoring that enables laboratories to achieve operational efficiency and increase productivity.
 

Related Links:
Abbott Diagnostics 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more